—
C+
C+ The full Closelook — membership. Open the C+ overview

Immunitybio Inc (IBRX) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Immunitybio Inc

IBRX in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
ImmunityBio is a biotechnology company that designs immunotherapies meant to activate the immune system against cancer and infectious disease. It develops several platforms, including engineered cytokine proteins, DNA-based vectors and cell therapies, aimed at solid and liquid tumours. Its approved product, Anktiva, treats a form of bladder cancer alongside an existing immunotherapy, and it holds licences and research partnerships with outside institutions. The company is based in San Diego.
Where it sits in the stack
ImmunityBio holds no seat in either of our indices, Rubin or Halo. It sits within the biotechnology sleeve of our universe, apart from the semiconductor and data-centre layers those indices track.
Who it is priced against
Closelook's peer group does not list a set for ImmunityBio. The immuno-oncology name the market most often mentions alongside it is Bristol-Myers Squibb.
Why Closelook tracks it
ImmunityBio carries a Closelook score, but only one module has been scored so far, so the read is still being built. It holds no seat in Rubin or Halo, and no quotes or editions currently reference the company in the diary.
What the diary watches
The diary watches whether clinical results for its cell and cytokine therapies, and market uptake of Anktiva, shift the picture beyond the current chart-based read.

Immunitybio Inc (IBRX) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for IBRX, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

This name carries no Closelook score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against IBRX on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 50/100 · S&P 500 fund at 49, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-18
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 97th percentile of the window, +4.9% over 20 sessions. Factor regime → 2026-09-18
  • Sovereign pressure Index 0.07 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-18

FAQ · from the current data · as of 2026-09-19

Quick answers

What is Immunitybio Inc (IBRX)?

Immunitybio Inc trades as IBRX on the US exchange (US) in the Closelook research universe, as of the registry build of 2026-09-19.

Is IBRX in a Closelook index?

Not currently — Immunitybio Inc is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-19.

Where does IBRX trade against its moving averages?

Uptrend stack intact: Trades +9.5% vs the 50-day and +23.5% vs the 200-day average, 31.8% below the 52-week high and +334.9% off the 52-week low. Computed from daily closes. As of 2026-09-18 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Immunitybio Inc do?

ImmunityBio is a biotechnology company that designs immunotherapies meant to activate the immune system against cancer and infectious disease. It develops several platforms, including engineered cytokine proteins, DNA-based vectors and cell therapies, aimed at solid and liquid tumours. Its approved product, Anktiva, treats a form of bladder cancer alongside an existing immunotherapy, and it holds licences and research partnerships with outside institutions. Closelook's peer group does not list a set for ImmunityBio. The immuno-oncology name the market most often mentions alongside it is Bristol-Myers Squibb.

Where does Immunitybio Inc sit in the AI build-out?

ImmunityBio holds no seat in either of our indices, Rubin or Halo. It sits within the biotechnology sleeve of our universe, apart from the semiconductor and data-centre layers those indices track. ImmunityBio carries a Closelook score, but only one module has been scored so far, so the read is still being built. It holds no seat in Rubin or Halo, and no quotes or editions currently reference the company in the diary.

What does this page show?

A live price chart with SMA overlays and drawing tools for IBRX, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.